Trends of drug use with suggested shortages and their alternatives across 41 real world data sources and 18 countries in Europe and North America
Pineda-Moncusi, M.; Rekkas, A.; Martinez Perez, a.; Leis, A.; Lopez Gomez, C.; Fey, E.; Bruninx, E.; Rodeiro, J.; Maljkovic, F.; Franz, M.; Mayer, M.-A.; Eleangovan, N.; Natsiavas, P.; Sen, S.; Cooper, S.; Reisberg, S.; Manlik, K.; Sanchez-Saez, F.; Pino, B. d.; Prats Uribe, A. P. U. A.; Yag?z Uresin, A.; Danilovic Bastic, A.; Rodrigues, A. M.; Palomar-Cros, A.; Verbiest, A.; Erdo?an, B.; Dinkel-Keuthage, C.; Torre, C. O.; Beukelaar, C. d.; Eteve-Pitsaer, C.; Goncalves, C. F.; Palma, C. d.; Gavina, C.; Dedman, D.; Price, D. B.; Balan, D. G.; Enders, D.; Henke, E.; Scheurwegs, E.; Callewaert, E
Show abstract
ImportanceDrug shortages leave affected patients in a vulnerable position. ObjectiveTo describe incidence and prevalence of use for medicines with suggested shortages in at least one European country, as announced by the European Medicines Agency, and to characterise the users of these drugs including the indication of use, duration of use, and dosage. DesignWe performed a descriptive cohort study from 2010 and up to 2024 in a network of databases which have mapped their data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). SettingSettings included primary care, secondary care, claims and various disease registries. ParticipantsWe included all patients with at least 365 days of history on the database. ExposuresAll medicines with a suggested shortage in at least one European country for more than 365 days (n=18). We also assessed their key alternatives (n=39). Main outcomes and measuresWe estimated annual incidence rates and period prevalence. A drop in incidence or prevalence of >33% after the shortage was announced was considered confirmation of a shortage. ResultsAmong 52 databases from Europe and the United States, we observed shortages according to decreased incidence of use for 8 drugs and shortages according to prevalence of use for 9 drugs. The drugs varenicline and amoxicillin alone or plus clavulanate were in shortage in the most number of countries. Conclusion and relevanceWe compiled and analysed data of annual incidence and prevalence of use plus information on patient characteristics, indication, and dose for 57 medicines among 52 databases in Europe and the United States between 2010 and 2024. We detected shortages and observed a change in the users characteristics for several drugs. We have described timely real-world scenarios of drug shortages and those unobserved in various health care settings and countries which helps to better understand how drug shortages play out in real life.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 95%
- Sales of over-the-counter products containing codeine in 31 countries, 2013-2019: a retrospective observational study 93%
- Large-scale empirical identification of candidate comparators for pharmacoepidemiological studies 93%
Similar papers in this journal
- INSIGHT: A Tool for Fit-for-Purpose Evaluation and Quality Assessment of Observational Data Sources for Real World Evidence on Medicine and Vaccine Safety 92%
- Using quantitative bias analysis to adjust for misclassification of COVID-19 outcomes: An applied example of inhaled corticosteroids and COVID-19 outcomes 90%
- The Medicines Intelligence Data Platform: A population-based data resource from New South Wales, Australia 90%
Similar papers in this journal
- Trends in analgesia prescribing in primary care in Ireland and England between 2014 and 2022 - a repeated cross-sectional study 93%
- People exposed to proton pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nation-wide matched cohort study 93%
- Preclinical Efficacy in Investigator’s Brochures: Stakeholders’ views on measures to improve Completeness and Robustness 91%
Similar papers in this journal
- Impact of non-pharmaceutical interventions against COVID-19 in Europe: a quasi-experimental study 91%
- Recording of 'COVID-19 vaccine declined' among vaccination priority groups: a cohort study on 57.9 million NHS patients' primary care records in situ using OpenSAFELY 90%
- Cluster of COVID-19 in northern France: A retrospective closed cohort study 88%
Similar papers in this journal
- Changes in dispensing of medicines proposed for re-purposing in the first year of the COVID-19 pandemic in Australia 94%
- Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients 93%
- Extent and causes of the collapse in the registration of innovative medications in Lebanon: A mixed-methods analysis 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.